Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTMT1 | Q9BV86 | 18/20 | 0.47 |
| ▸ | UGCG | Q16739 | 1/20 | 0.45 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856674 | 1.00 | NTMT1 (0.47) | NTMT1UGCGHAO1GSK3BDYRK1A | |
| SCHEMBL2851660 | 1.00 | NTMT1 (0.47) | NTMT1UGCGHAO1GSK3BDYRK1A | |
| Formic Acid SCHEMBL2855542 | 0.97 | NTMT1 (0.45) | NTMT1UGCGHAO1GSK3BDYRK1A | |
| Formic Acid SCHEMBL2855811 | 0.97 | NTMT1 (0.45) | NTMT1UGCGHAO1GSK3BDYRK1A | |
| SCHEMBL2854404 | 0.93 | NTMT1 (0.47) | NTMT1UGCG | |
| SCHEMBL2854402 | 0.93 | NTMT1 (0.47) | NTMT1UGCG | |
| SCHEMBL2851481 | 0.93 | NTMT1 (0.47) | NTMT1UGCG | |
| SCHEMBL2855643 | 0.92 | NTMT1 (0.49) | NTMT1UGCGHAO1 | |
| SCHEMBL2862222 | 0.92 | NTMT1 (0.49) | NTMT1UGCGHAO1 | |
| Formic Acid SCHEMBL2854176 | 0.90 | NTMT1 (0.45) | NTMT1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103237801-B | Quinoline or quinazoline derivatives having apoptosis-inducing activity on cells | HANMI HOLDINGS Co.,Ltd. (KR) | 2015-11-25 | — | — | CN | claimed |
| CN-103237801-A | Quinoline or quinazoline derivatives having apoptosis-inducing activity on cells | HANMI HOLDINGS CO LTD | 2013-08-07 | — | — | CN | claimed |
| EP-1828179-B1 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AGAINST CNS-RELATED DISEASES | MEMORY PHARM CORP (US) | 2010-01-20 | — | — | EP | claimed |
| US-7625924-B2 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-12-01 | — | — | US | claimed |
| US-20060167039-A1 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-27 | — | — | US | claimed |
| US-20240360147-A1 | Process for Synthesizing Naphthyridine Derivatives and Intermediates Thereof | AMGEN INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240293386-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR | LG CHEM, LTD. (KR) | 2024-09-05 | — | — | US | disclosed |
| EP-4332106-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR | LG Chem, Ltd. (KR) | 2024-03-06 | — | — | EP | disclosed |
| WO-2023034786-A1 | PROCESS FOR SYNTHESIZING NAPHTHYRIDINE DERIVATIVES AND INTERMEDIATES THEREOF | AMGEN INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| CN-110300754-A | Pyrrolo [1,2-b ] pyridazine derivatives | 吉利德科学公司 | 2019-10-01 | — | — | CN | disclosed |
| CN-106470994-B | For treating the substituted pyrazine of CNS disease simultaneously [2,1-A] isoquinilone derivatives | 豪夫迈·罗氏有限公司 | 2019-09-24 | — | — | CN | disclosed |
| CN-110156772-A | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-101068797-A | Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof | MITSUBISHI PHARMA CORP (JP) | 2007-11-07 | — | — | CN | disclosed |
| EP-1828179-A2 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF | Memory Pharmaceutical Corporation (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
| CN-101006076-A | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2007-07-25 | — | — | CN | disclosed |
| CN-1926121-A | Thiazole derivatives and uses thereof | APPLIED RESEARCH SYSTEMS (AN) | 2007-03-07 | — | — | CN | disclosed |
| CN-1902201-A | Bicyclic pyrimidin-4-(3H)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (VR1) | MERCK SHARP & DOHME (GB) | 2007-01-24 | — | — | CN | disclosed |
| US-20060167039-A1 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006069097-A2 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360147-A1 | Process for Synthesizing Naphthyridine Derivatives and Intermediates Thereof | NME1, NPM1, NME2 | NTMT1 310/4885UGCG 1348/4885HAO1 2497/4885 |
| US-20060167039-A1 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA6 | NTMT1 927/4885UGCG 2056/4885HAO1 2436/4885 |
| US-20240293386-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR | MAP3K20, SBK3, MAPKAPK2 | NTMT1 1554/4885UGCG 3492/4885HAO1 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.